VT-1092

Primary purpose: To evaluate the safety and tolerability of single and multiple intratumoral administration of VT1092 in subjects with recurrent or metastatic solid tumors, explore the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in humans, and recommend a safe dose range for subsequent extended trials and Phase II clinical studies of this product. Secondary purpose: To evaluate the biodistribution and biological effects of single and multiple intratumoral administration of VT1092 in humans. Preliminary evaluation of the objective response rate (ORR) and disease control rate (DCR) of VT1092 in the treatment of recurrent or metastatic solid tumors.